Roche Webinar: HER2 IHC testing in the wake of the 2023 HER2 Breast Guideline Update
HER2 IHC testing in the wake of the 2023 HER2 Breast Guideline Update
Clinical Value, Classification & Scoring and the impact of the ASCO-CAP 2023 HER2 Breast Testing Guideline Update
Over the past several months, the HER2/neu IHC testing landscape in breast cancer has evolved. The PATHWAY HER2/neu (4B5) Rabbit Monoclonal Primary Antibody is the first and only FDA-approved immunohistochemistry companion diagnostic test for interpreting all levels of HER2 protein expression including HER2-low.
This comprehensive session aims to support pathologists with clinical training to better understand the spectrum of HER2 IHC expression for identifying breast cancer patients who are eligible for treatment with Herceptin® (IHC 3+ or IHC 2+/ISH amplified), KADCYLA® (IHC 3+ or IHC 2+/ISH amplified) or ENHERTU® (IHC 1+ or IHC 2+/ISH non-amplified).
This session will also cover a pathologist perspective of the impact of the ASCO-CAP HER2 Testing in Breast Cancer 2023 Guideline Update and will include a slide review of challenging cases.
Wednesday, September 27
11:00 AM Pacific/2:00 PM Eastern
Learning Objectives:
- Provide the diagnostic landscape of HER2 IHC Testing and the clinical trial data to support it
- Discuss Scoring and Interpretation of HER2 in Breast Cancer, Including Challenging Cases
- Understand the impact of the ASCO/CAP HER2 Testing in Breast Cancer 2023 Guideline Update
https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer
Audrey Bennett, MD
Pathology Liasion Roche Medical & Scientific Affairs
The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through Roche. This activity is not available for CME.
SOURCE: Roche
